Skip to content
PulseMS
Log inJoin
Research & community

MS research, together.

MS research in plain English. Perspectives from people who understand.

Research evidence filters

Filters apply to reviewed research. Unknown dates and unassessed posts are excluded when a corresponding filter is active.

Reset filters
Topics & sourcesFiltered
Research and community updates, newest first.#BiomarkersAI researchClear filters
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyObservationalTrial registry

Immune Biomarkers in Patients with Relapsing Remitting Multiple Sclerosis: Observational Study on Autologous Haematopoietic Stem Cell Transplantation (aHSCT)

An observational study is currently recruiting 15 patients with relapsing remitting multiple sclerosis to investigate the immune profiles in those treated with autologous haematopoietic stem cell transplantation compared to those receiving high efficacy disease modifying treatment over 24 months.

What this does not proveNo results are available yet, as the trial is still recruiting. The mechanisms of aHSCT in MS are not fully understood, and it remains unclear which patients might benefit from treatment.
#Biomarkers
View abstract on PubMedAI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyLaboratoryPeer review unconfirmed

Human CSF Endopeptidome Study in MS and NMOSD

In a laboratory analysis, researchers identified 381 endogenous peptides in the cerebrospinal fluid (CSF) of treatment-naïve patients with clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), and neuromyelitis optica spectrum disorder (NMOSD). A specific C-terminal peptide from secretogranin-5 was notable for decreasing in abundance from CIS to RRMS. NMOSD patients showed reduced peptide levels and oxidative modifications.

What this does not proveThe study is exploratory; it does not provide definitive clinical utility or validate findings across larger patient groups, limiting its applicability.
#Biomarkers
View abstract on PubMedPMID 42831274AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyNot reportedPeer review unconfirmed

Diagnostic Value of κ-FLC in OCB-Negative Patients

In a study of 141 human patients, 83% had measurable cerebrospinal fluid (CSF) κ-FLC, and 43% had a positive κ-FLC index. The findings suggested that an MS diagnosis could have been made 4.9 months earlier for patients who met the dissemination in space (DIS) criteria but not dissemination in time (DIT) criteria.

What this does not proveThe study is retrospective and focused on a specific cohort, which may limit how widely the results can be applied.
#Biomarkers
View abstract on PubMedPMID 42756799AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyNot reportedTrial registry

Human Study on Serum Cytokine TWEAK in Multiple Sclerosis

A study involving 50 human subjects investigated the serum concentration of the cytokine TWEAK over a year. It was observed that variations in TWEAK levels correlate with inflammatory disease outbreaks in Multiple Sclerosis (MS).

What this does not proveAs results are not posted, the findings are preliminary and do not confirm causation or effective treatment effects. Planned enrollment and endpoints do not constitute findings.
#Biomarkers
View abstract on PubMedAI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyNot reportedPeer review unconfirmed

Human MS Patients and Biomarkers IFNG-AS1 and UCHL1-AS1

In a study comparing 120 MS patients and 100 healthy controls, expressions of the long noncoding RNAs IFNG-AS1 and UCHL1-AS1 were significantly decreased in MS patients (p < 0.0001). Even after adjusting for age, IFNG-AS1 remained significantly lower in MS patients, suggesting it may serve as a potential biomarker for MS diagnosis (AUC = 0.838).

What this does not proveThe findings are preliminary and need further validation through functional studies to establish their clinical relevance.
#Biomarkers
View abstract on PubMedPMID 42763619AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studySystematic reviewPeer review unconfirmed

Role of Cytokines and MMPs in Multiple Sclerosis Pathogenesis

A systematic review identified key cytokines (like IL-3, IL-5, IL-6, and MMPs) as critical drivers of neuroinflammation and neurodegeneration in multiple sclerosis (MS). MMP-1 could differentiate early MS from clinically isolated syndrome, while IL-9, IL-10, and IL-13 may be targets for neuroprotective strategies.

What this does not proveThe findings do not confirm any treatment effectiveness and lack clinical trial data for validation.
#Biomarkers#Cytokines#Immunomodulation#NeuroprotectionRelevant to Neurologist, Immunologist
View abstract on PubMedPMID 42794509AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyObservationalPeer review unconfirmed

Longitudinal Gut Microbiome Study in Relapsing-Remitting MS Patients

In a study of 29 treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS), gut microbiota composition and diversity remained stable over one year. While there was a trend indicating that worsening disability (measured by EDSS) correlated with increased microbiome instability, this did not reach statistical significance. Additionally, GFAP levels increased significantly, while NfL levels decreased and S100B levels remained unchanged.

What this does not proveThe study's exploratory analyses noted that significant associations found did not hold after adjustments for multiple testing. Moreover, the small sample size necessitates larger longitudinal studies to better understand these relationships.
#GutHealth#Disability#Biomarkers#SymptomMgmtRelevant to Neurologist, Immunologist
View abstract on PubMedPMID 42795661AI summary of a published abstract. Not medical advice.
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedHuman studyObservationalPeer review unconfirmed

Human Subjects Research on Serum GFAP and Age in NMOSD Diagnosis

In a study of 640 patients, serum GFAP levels and age effectively differentiated various neuromyelitis optica spectrum disorders (NMOSD), particularly AQP4-NMOSD, from other conditions like MOGAD. The study found high diagnostic accuracy measured by area under the curve (AUC), indicating strong potential for these biomarkers in clinical diagnosis.

What this does not proveThe findings are limited to differentiating NMOSD from other diseases and do not reflect treatment efficacy or direct clinical outcomes.
#Biomarkers#Diagnosis#NMOSDRelevant to Neurologist, Immunologist
View abstract on PubMedPMID 42798289AI summary of a published abstract. Not medical advice.